MA53616A - Protéines bispécifiques modifiées - Google Patents
Protéines bispécifiques modifiéesInfo
- Publication number
- MA53616A MA53616A MA053616A MA53616A MA53616A MA 53616 A MA53616 A MA 53616A MA 053616 A MA053616 A MA 053616A MA 53616 A MA53616 A MA 53616A MA 53616 A MA53616 A MA 53616A
- Authority
- MA
- Morocco
- Prior art keywords
- modified
- specific proteins
- proteins
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53616A true MA53616A (fr) | 2022-05-04 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053616A MA53616A (fr) | 2018-08-16 | 2019-08-15 | Protéines bispécifiques modifiées |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (enExample) |
| EP (1) | EP3850007A4 (enExample) |
| JP (1) | JP7397063B2 (enExample) |
| KR (1) | KR20210064199A (enExample) |
| CN (1) | CN112839955A (enExample) |
| AU (1) | AU2019320803A1 (enExample) |
| BR (1) | BR112021002730A2 (enExample) |
| CA (1) | CA3109763A1 (enExample) |
| EA (1) | EA202190542A1 (enExample) |
| IL (1) | IL280882A (enExample) |
| MA (1) | MA53616A (enExample) |
| MX (1) | MX2021001711A (enExample) |
| SG (1) | SG11202101273VA (enExample) |
| WO (1) | WO2020037150A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| BR112022012230A2 (pt) | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CR20230178A (es) * | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| WO2023114499A1 (en) * | 2021-12-17 | 2023-06-22 | Denali Therapeutics Inc. | Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| IL318627A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Anti-TFR charge fusions and methods of using them |
| MA71631A (fr) | 2022-07-29 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblées vers le récepteur 1 de transferrine |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| KR20260021596A (ko) | 2023-04-05 | 2026-02-13 | 아이오니스 파마수티컬즈, 인코포레이티드 | Pln 발현을 감소시키는 화합물 및 방법 |
| AR133384A1 (es) | 2023-07-28 | 2025-09-24 | Regeneron Pharma | Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida |
| IL326018A (en) | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1697520A2 (en) * | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP4624490A3 (en) * | 2012-02-09 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Modified fc region of antibody |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| US10562973B2 (en) * | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| JP7021955B2 (ja) | 2015-06-24 | 2022-03-03 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法 |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| CA3053381A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| RS63818B1 (sr) * | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| CA3053379A1 (en) * | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| BR112020005271A2 (pt) * | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| BR112020013921A2 (pt) * | 2018-01-10 | 2020-12-01 | Denali Therapeutics Inc. | polipeptídeos de ligação ao receptor de transferrina e usos destes |
| WO2019246071A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210064199A (ko) | 2021-06-02 |
| MX2021001711A (es) | 2021-05-27 |
| EP3850007A2 (en) | 2021-07-21 |
| CN112839955A (zh) | 2021-05-25 |
| AU2019320803A1 (en) | 2021-03-11 |
| WO2020037150A2 (en) | 2020-02-20 |
| IL280882A (en) | 2021-04-29 |
| JP7397063B2 (ja) | 2023-12-12 |
| US20220017634A1 (en) | 2022-01-20 |
| EA202190542A1 (ru) | 2021-09-07 |
| CA3109763A1 (en) | 2020-02-20 |
| WO2020037150A3 (en) | 2020-10-15 |
| EP3850007A4 (en) | 2022-08-10 |
| BR112021002730A2 (pt) | 2021-08-10 |
| JP2021533779A (ja) | 2021-12-09 |
| SG11202101273VA (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3850007A4 (en) | Engineered bispecific proteins | |
| IL272227A (en) | Anti-tigit antibodies | |
| IL269405A (en) | Anti-sirp alpha antibodies | |
| IL272466A (en) | Antigen-binding proteins targeting shared antigens | |
| IL268620A (en) | Anti-lag3 antibodies | |
| KR102763158B9 (ko) | 최적화된 항tl1a 항체 | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| PT3649151T (pt) | Proteínas de suporte | |
| EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
| EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
| IL281804A (en) | Protein purification methods | |
| EP3880814A4 (en) | FUSION PROTEIN | |
| IL254516B (en) | Proteins specific for cd137 | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODY | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| DK3743337T3 (da) | Vilkårlig kasselukker | |
| DK3737403T3 (da) | Modificerede adenovira | |
| DK3737402T5 (da) | Modificeret protein | |
| CL2018000520A1 (es) | Proteinas inhibidoras de insectos novedosas | |
| IL281594A (en) | Anti-klrg1 antibodies | |
| EP3522698A4 (en) | NEW INSECTICIDE PROTEINS | |
| DK3452515T3 (da) | Her-2-bindende antistoffer | |
| EP3751266A4 (en) | SAMPLE HOLDER | |
| EP3579879A4 (en) | ANTI-BODY ANTI-KIR3DL1 |